Dabigatran antidote gets TGA green light
The first reversal agent for a direct-acting oral anticoagulant (DOAC) has been approved by the TGA.
Idarucizumab (Praxbind) is a monoclonal antibody that reverses the anticoagulant effect of dabigatran (Pradaxa) in patients who require emergency surgery or have life-threatening bleeding.
The reversal effect is specific to dabigatran.
“It is an antibody to the drug itself and it works almost instantly,” says cardiologist Associate Professor David Colquhoun of the University of Queensland and the Greenslopes Private Hospital